Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Naunyn Schmiedebergs Arch Pharmacol ; 386(7): 645-50, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23564042

ABSTRACT

Accumulating evidence shows that iron overload is a new risk factor for diabetes mellitus. L-type Ca(2+) channel (LTCC) has been identified as an important mediator for ferrous iron uptake into cardiomyocytes. In this study, we aimed to examine the effects of verapamil, the LTCC blocker, on myocardial iron metabolism in diabetic rats. Diabetes was induced by intraperitoneal injection of streptozocin after intragastric administration of fat emulsion, and then treated by verapamil (5 mg · kg(-1) · day(-1)) for 1 week. The results showed that verapamil did not alter the blood glucose level of diabetic rats. However, elevated levels of superoxide dismutase, malonaldehyde, and serum ferritin in diabetic rats were decreased significantly by verapamil treatment. Moreover, serum, myocardial, and urine iron were elevated remarkably along with a decrease of hepatic iron in diabetic rats. After verapamil administration, serum and myocardial iron in diabetic rats were reduced significantly but urine and hepatic iron were increased. Furthermore, confocal microscopy demonstrated that intracellular-free iron concentration was elevated dramatically in cardiomyocytes of diabetic rats, which was markedly attenuated after verapamil treatment. In summary, our data demonstrated that verapamil prevented myocardial iron overload by inhibiting intracellular iron accumulation in diabetic cardiomyocytes.


Subject(s)
Anti-Arrhythmia Agents/therapeutic use , Calcium Channel Blockers/therapeutic use , Diabetes Mellitus, Experimental/drug therapy , Iron Overload/drug therapy , Verapamil/therapeutic use , Animals , Anti-Arrhythmia Agents/pharmacology , Blood Glucose/analysis , Calcium Channel Blockers/pharmacology , Diabetes Mellitus, Experimental/metabolism , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Iron/metabolism , Iron Overload/metabolism , Liver/metabolism , Male , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/metabolism , Rats , Rats, Wistar , Streptozocin , Verapamil/pharmacology
2.
Naunyn Schmiedebergs Arch Pharmacol ; 380(5): 443-50, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19685039

ABSTRACT

We have studied the association between M(3) muscarinic acetylcholine receptors (M(3)-mAChR) and protein kinase C-epsilon (PKC-epsilon) during ischemic myocardial injury using Western blot analysis and immunoprecipitation technique. Myocardial ischemia (MI) induced PKC-epsilon translocation from cytosolic to membrane fractions. This translocation participated in the phosphorylation of M(3)-mAChR in membrane fractions, which could be abolished by the inhibitor of PKC, chelerythrine chloride. On the other hand, M(3)-mAChR could also regulate the expression of PKC-epsilon in ischemic myocardium. Choline (choline chloride, an M(3) receptor agonist, administered at 15 min before occlusion) strengthened the association between PKC-epsilon and M(3)-mAChR. However, blockade of M(3)-mAChR by 4-diphenylacetoxy-N-methylpiperidine methiodide (an M(3) receptor antagonist, administered at 20 min before occlusion) completely inhibited the effect of choline on the expression of PKC-epsilon. We conclude that the translocation of PKC-epsilon is required for the phosphorylation of M(3)-mAChR; moreover, increased PKC-epsilon activity is associated with M(3)-mAChR during MI. This reciprocal regulation is likely to play a role in heart signal transduction during ischemia between ventricular myocytes.


Subject(s)
Myocardial Ischemia/physiopathology , Myocytes, Cardiac/metabolism , Protein Kinase C-epsilon/metabolism , Receptor, Muscarinic M3/metabolism , Animals , Blotting, Western , Immunoprecipitation , Male , Phosphorylation , Protein Transport , Rats , Rats, Wistar , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...